The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taki 22 May 2024
Executives at cash-strapped biotech Lyra Therapeutics are hoping a drastic reduction in headcount will help keep the lights on, alongside other cost-cutting mea 22 May 2024
A new subcutaneous version of the checkpoint blocker Opdivo (nivolumab) could be approved earlier than expected, after the US regular brought forward the date f 22 May 2024
Data have been presented from the NOTUS Phase III study on the use of Dupixent (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD o 21 May 2024
US healthcare giant Johnson & Johnson has announced that the Tremfya (guselkumab) QUASAR maintenance study in ulcerative colitis (UC) met its primary endpoint a 21 May 2024
Australian radiopharma developer Telix Pharmaceuticals has filed for a secondary listing, with proposals for an initial public offering in the USA. 20 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.